Table 5 Correlation between CDH1 haplotype frequencies and clinicopathological characteristics of breast cancer patients

Age at diagnosis

 ≤40

0.358

0.213

0.194

0.084

0.027

0.094

0.030

 >40

0.312

0.248

0.173

0.117

0.081

0.032

0.036

 P

0.15

0.83

0.15

0.015

0.01

0.21

 OR (CI 95%)

1

1.38 (0.89–2.13)

1.06 (0.64–1.74)

1.54 (0.85–2.79)

3.74 (1.29–10.82)

0.37 (0.17–0.79)

1.37 (0.82–2.28)

Menopausal status

 Non menopausal

0.354

0.236

0.172

0.105

0.056

0.049

0.028

 Menopausal

0.291

0.245

0.182

0.114

0.081

0.043

0.044

 P

0.21

0.26

0.26

0.098

0.92

0.25

 OR (CI 95%)

1

1.26 (0.88–1.81)

1.29 (0.83–2.01)

1.29 (0.83–2.01)

1.69 (0.91–3.16)

1.04 (0.51–2.11)

1.73 (0.64–4.39)

Tumor size

 T1–T2

0.318

0.237

0.192

0.105

0.057

0.051

0.038

 T3–T4

0.326

0.242

0.149

0.124

0.085

0.038

0.035

 P

0.91

0.23

0.6

0.33

0.46

0.76

 OR (CI 95%)

1

0.98 (0.65–1.46)

0.73 (0.44–1.21)

1.13 (0.71–1.81)

1.41 (0.71–2.79)

0.74 (0.33–1.66)

0.86 (0.32–2.27)

Lymph node involvement

 Negative

0.320

0.284

0.162

0.084

0.053

0.047

0.050

 Positive

0.323

0.208

0.195

0.123

0.080

0.047

0.023

 P

0.19

0.34

0.24

0.29

0.91

0.19

 OR (CI 95%)

1

0.78 (0.54–1.13)

1.26 (0.78–2.04)

1.34 (0.82–2.17)

1.43 (0.74–2.77)

0.96 (0.47–1.95)

0.55 (0.22–1.81)

SBR grade

 SBR 1–2

0.314

0.225

0.167

0.131

0.086

0.047

0.030

 SBR 3

0.365

0.230

0.192

0.085

0.040

0.055

0.025

 P

0.46

0.96

0.053

0.049

0.97

0.84

 OR (CI 95%)

1

0.86 (0.57–1.29)

0.99 (0.61–1.61)

0.61 (0.37–1.00)

0.44 (0.19–0.99)

1.01 (0.50–2.05)

0.91 (0.34–2.42)

Histology

 Ductual

0.291

0.231

0.139

0.157

0.122

0.026

0.032

 Lobular

0.329

0.245

0.179

0.103

0.060

0.050

0.033

 P

0.74

0.83

0.2

0.11

0.52

0.72

 OR (CI 95%)

1.00

1.12 (0.57–2.22)

0.90 (0.35–2.34)

1.59 (0.78–3.23)

2.06 (0.86–4.94)

0.62 (0.14–2.67)

0.91 (0.54–1.52)